Amgen Reports 8% Revenue Growth and $6.45 Adjusted EPS in Q3 2026

What happened

Amgen reported third-quarter 2026 revenue of $10.4 billion, up 8% from a year earlier, and adjusted earnings per share (EPS), or profit allocated to each share, of $6.45. It maintained its full-year revenue and EPS guidance ranges.

Confirmed

Global impact / market context

Higher revenue and earnings alongside maintained annual guidance indicate that the reported quarter did not lead Amgen to change its stated full-year outlook. Product growth could support sales, while declines for Prolia and XGEVA amid biosimilar launches show competition weighing on parts of the business.

Analyst inference

The article reports mixed operating signals: 17 products had double-digit sales growth, but Prolia and XGEVA declined amid biosimilar launches. Free cash flow, meaning cash remaining after operating needs and investment, fell year over year, which may limit cash available for other uses.

Analyst inference

What to watch

1. Compare future revenue and earnings with the maintained full-year guidance ranges of $38.9 billion to $39.7 billion and $22.90 to $23.70 in adjusted EPS. Analyst inference
2. Watch whether Prolia and XGEVA declines continue as biosimilar competitors launch, since sustained losses could offset sales growth from other products. Analyst inference
3. Track MariTide Phase 3 progress: the MARITIME-CV and two MARITIME-OSA studies had completed enrollment, while other studies were continuing. Confirmed

Evidence

• Original source link unavailable